Resources

Whether new clinical results support your brand or a new competitor is challenging it, rapid turn-around market research can help enhance manufacturers’ understanding of key market events or unexpected changes in the market.

PULSE Analytics is the most comprehensive suite of tools that provides analytics and data on providers, clinical pathways, and payer policies.

Learn more about MMIT Analytics and how it can benefit your organization.

Integrated RWD from claims, labs, and other sources is instrumental to a successful market access strategy. This executive summary of a BioPharma Dive webinar explains how RWD helps manufacturers uncover and resolve patient access barriers.

Learn how a manufacturer used MMIT’s custom market research to assess the value of their product in the asthma treatment space and address unmet marketplace needs.

Learn how a manufacturer used MMIT’s custom market research to find how their product would be assessed during the clinical and financial review portions of a P&T session.

Learn how a manufacturer used MMIT’s custom market research to determine how it’s viewed in the marketplace in a variety of categories across time and against analog companies.

Learn how a manufacturer used MMIT’s custom market research to inform launch pricing and access strategy for their new product.

Learn how KORU Medical Systems used claims and payer coverage data to better understand reimbursement and improve patient access to its devices.

Give your messaging more impact with MMIT’s Custom Communication Program + Message Monitor.

Learn how one biopharma company prepared for a new competitor by analyzing past market analogs and sales trends.

Learn how MMIT collects and analyzes real-world data and transforms it into actionable insights.

MMIT’s real-world data solution uses multiple data points and insights to help manufacturers understand each step of the patient journey.

MMIT’s real-world data solution provides critical insights for manufacturers across the clinical and commercial life cycle.

Payer Landscape provides organizations across healthcare a simple way to understand and segment health plan accounts by lives, channel and geography.

The Directory of Health Plans (DHP) provides organizations across healthcare with current and comprehensive health plan enrollment data.

A pharma company with several approved brands with large market share was developing a new Crohn’s disease drug. The company partnered with MMIT to determine whether the new drug would be approved in the marketplace

Oncology therapy pricing and contracting trends help inform manufacturers on competitive benchmarks, offering types, impact and potential levers to deploy in support of portfolio value perceptions and performance.

In the rapidly evolving distribution landscape, it is important to track analog model design trends, customer preferences, and vendor capabilities. Ensure product distribution models align to customer preferences and expectations within a therapeutic area.

Learn more about MMIT’s Multi Channel Message Testing solution.

Learn more about MMIT’s Payer Messaging Playbook solution.

Gain insight on manufacturers restrictions on covered entities and understand account response strategy with the Access Impact of Manufacturers’ 340B Restrictions Syndicated Report.

Learn more about why it is critical for manufacturers to understand these vendors and patient access implications, in order to formulate a response strategy to ensure appropriate therapy coverage and optimal patient access.

Learn how one biotech company used MMIT’s Analytics, Surveillance, FormTrak and Coverage Search tools to achieve its launch goals early.

Learn how a healthcare IT organization was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Learn more about MMIT’s Syndicated Reports solution.

Download our infographic to learn the depth of information you can access with our newest databases.

In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in breast cancer.

In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in rheumatoid arthritis.

In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in migraine.

In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in non-small cell lung cancer.

In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in atopic dermatitis.

In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in oncology biosimilars.

Your team needs a variety of resources to develop a successful payer strategy. Download this infographic to learn how MMIT can help your organization.

Connecting with the right healthcare stakeholders about your brand is difficult. Learn how RJ Health, an MMIT company, can make it simpler.

Learn how a P&T review helped one pharma company understand how its product would be assessed, leading to a new focus on gathering real-world evidence.

Hear from pharmaceutical companies already using Contract Validation about how the solution has changed their workflow.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Gain comprehensive insight into formulary and medical benefit coverage, covered lives, and policy and restriction information.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn more about MMIT’s RC Claim Assist solution.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn more about MMIT’s Rapid Response solution.

Learn more about MMIT’s Engage solution.

Struggling to capture your organization’s performance? Learn how MMIT can provide unblinded feedback to help guide decision-making with our Satisfaction Surveys.

Open to learn why MMIT’s Lab Data is the best solution for longitudinal tracking of patients.

RJ Health, an MMIT company, conducted a survey on NDC mandates. In 2016 and 2021, we asked payers questions such as how they are managing NDCs and who performs unit conversions. We compiled these results

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn more about MMIT’s Bridging as a Service solution.

Inform site selection, drive trial awareness and enrollment, and uncover patient-centric signals for evidence generation and outcomes studies.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Contracting in pharma has grown increasingly complex, which results in significant rebate leakage for manufacturers. Recent MMIT research highlights the severity of the problem.

How MMIT’s longstanding advisory relationship with a global pharmaceutical company helped transform its portfolio strategy.

Learn how pharma companies that were early adopters of MMIT’s FormTrak integration in Veeva CRM see the new functionality changing their workflow.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Understanding and maintaining insight into payer enrollment is difficult. At MMIT, we are focused on helping our clients understand the complex payer landscape.

How Medical Billing and Coding Can Impact Patient Access. Hear from the experts from RJ Health, an MMIT company.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Patient assistance programs can have an enormous impact on the time-to-treatment for prescribers and patients. Your ability to establish a patient assistance program strategy, especially when there are barriers to prescribing.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn more about MMIT’s proactive, economic, precise, and comprehensive solution that can help manufacturers promote their therapies to specific providers using lab test results before a diagnosis and/or prescribing decision is made.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Learn how a pharma company leveraged MMIT’s Strategic Launch Report combined with In-Depth Interviews to get a unique view into the market access path for its therapy.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn more about MMIT’s Surveillance solution.

Learn how Patient Access Analytics from MMIT and Panalgo can show how coverage decisions influence physician prescriber behavior.

Learn how a product’s placement on pathways affects its utilization and uptake, and ultimately, patient’s access to life saving therapies.

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Read a summary of the Patient Access Analytics solution from MMIT and Panalgo.

MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

Learn how MMIT and MarketLauncher helped a medtech company engage a difficult-to-reach health plan audience.

Learn more about MMIT’s Formulary Navigator solution.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn how RJ Health helped a niche healthcare company bolster its payer communications.

Learn how a data-driven market access strategy and competitor benchmarking led to launch excellence.

Learn how a healthcare services company partnered with MMIT to help support its provider network with coverage data.

Contract Validation is a workflow automation platform that enables manufacturers to validate formulary positioning at scale by crosschecking the contract language against MMIT’s industry-leading data.

MMIT’s FormTrak tool helps prescribers get their patients on the right therapy even amid complex drug coverage requirements. FormTrak’s integration in Veeva CRM, pharma field teams can deliver an access message right in Veeva’s platform.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.

MMIT’s new FormTrak integration in Veeva CRM changes how pharma companies detail healthcare providers. Now your field teams can access FormTrak seamlessly within Veeva thanks to the first native market access integration.

Learn how a small pharma company leveraged MMIT’s Analytics platform to drive its messaging with healthcare providers as it launched its first commercial product at the start of the COVID-19 pandemic.

Learn more about MMIT’s FormTrak integration with Veeva CRM.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Learn how a pharma company partnered with MMIT’ to understand payer perceptions of its brand over time as competitors enter the market.

Learn how a pharma company preparing for a drug launch partnered with MMIT to gain insight into the most effective messaging with payers.

Understanding a large complex payer and their subsidiaries to segment your contracting plan or recognizing lives enrollment shifts in specific geographies, having payer data source solution to support your sales and marketing team is crucial.

Payer coverage policies continue to become more complex with increasing access hurdles. Dig into ways to sift through the noise and uncover payer account intervention and pull-through opportunities via dashboards and real-time alerts.

Without the right tools, your account managers will face many obstacles trying to win more pharma business. We’ll give you our top tips on how to engage with pharma manufacturers and differentiate your organization.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

Learn how formularies are currently managed, examine some of the key challenges faced by payers and PBMs, and evaluate new integrated solutions to optimize management of both pharmacy and medically covered drugs.

Learn how a pharma company leveraged MMIT’s advisory board service to get unique insights from payers and physician key opinion leaders (KOLs) to support its drug launch.

Learn how a pharma company’s market access team leveraged MMIT’s quantitative online surveys to obtain a custom pricing and contracting study to support its drug launch.

Factors complicate the payer enrollment landscape, making it challenging to project membership rolls across payers, geographies and channels. See enrollment projections, the drivers behind them and what you can expect from the 2021 payer landscape.

Learn how a medical device company partnered with and leveraged MMIT’s Payer Landscape data.

Learn how claims reimbursement is currently being managed, as well as some best practices for leveraging specialty drug data to streamline the process.

Learn how a healthcare IT organization automated payer account identification and outreach.

Take a look into how a PBM was able to gain a deeper understanding of their market potential and obtain competitive intelligence with Payer Landscape.

Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

As specialty pharmaceuticals consume an ever-larger share of healthcare benefit dollars, payers, providers and other healthcare organizations are realizing the importance of managing drugs administered under the medical benefit, which most often are specialty drugs.

Access barriers to the use of innovative technology such as administrative burden and reimbursement challenges. We will also touch upon payer concern about costs which might be underlying these issues.

Learn when and how to select the right analogs to set the most accurate expectations and payer strategy at launch.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Access dozens of payer profiles and in-depth narratives, focused on top health plans, PBMs and all 50 U.S. states.

Why aren’t pharma teams shifting market access strategies to earlier phases of drug development? The influence of payers and PBMs is often poorly understood.

Take a look into how a specialty pharmacy partnered with MMIT to enhance its referral process and decrease time to therapy for patients.

MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

P&T Session Heart Failure:  MMIT recently conducted a syndicated simulated P&T Heart Failure session focused on the entry Farxiga, and anticipated entry of Jardiance, into heart failure.

View a demo of the Payer Landscape tool.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.